Related Experiment Video
Updated: Jun 9, 2025
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
INTRAVITREAL INJECTION CONBERCEPT IMPROVES THE BEST-CORRECTED VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR
1Department of Ophthalmology, Jiaozhou Center Hospital of Qingdao, Qingdao, 266300, China.
Abstract:
The aim of the study was to investigate the value of intravitreal injection conbercept on the best-corrected visual acuity in patients with age-related macular edema.
Methods:
In this study, 114 patients (114 eyes) were treated with intravitreal injection of Conbercept in our hospital from August 2020 to January 2022. According to the clinical effect after treatment, they were divided into effective group (78 cases, 78 eyes) and ineffective group (36 cases, 36 eyes). All patients were continuously treated with intravitreal injection of Conbercept. The best corrected visual acuity (BCVA) was compared between the two groups.
Results:
Before treatment, the BCVA was compared between the effective group and the ineffective group (P>0.05). After 1, 2, and 3 times of treatment, the BCVA values of the effective group were lower than those of the ineffective group, and the BCVA changes of the effective group before and after treatment were greater than those of the ineffective group (P<0.05).
Conclusion:
The BCVA values of the effective group were lower than those of the ineffective group, and the BCVA changes of the effective group before and after treatment were greater than those of the ineffective group, suggesting that conbercept can improve the visual acuity of patients with macular edema caused by wet age-related macular degeneration.
